Brabant Development Agency (BOM) and angel investor join lead investor Libertatis Ergo Holding (LEH) in providing funding, with additional financial support from Brabant Startup Fund (BSF) Cantoni awarded validatioNN grant from Novo Nordisk to support disease-relevant translational research on NNMT, a novel target for cardiometabolic diseases, including obesity and its comorbidities September 16, 2025 - Cantoni Therapeutics B.V. (‘Cantoni’), a biotech company spun out from Leiden University, de

-- Upsized Series A Financing Brings Total Amount Raised to $133 Million -- -- GAD Affects 3.1% of U.S. Adult Population; Minority of Patients Receive Treatment -- -- Reunion Expects to Initiate RECLAIM Phase 2 Trial Evaluating RE104 for GAD in 1Q 2026 -- Sept. 16, 2025-- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeu

Sept. 15, 2025 -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply TEMBEXA® (brincidofovir) oral suspension. This follows the U.S. Food and Drug Administration’s (FDA) recent approval of the manufacturing scale-up of TEMB

The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to start the IND-enabling program for the NN-840 program with an IND submission expected next year This NIH grant award strongly confirms the scientific and clinical promise of the innovative approach of NanoNewron to treat Alzheimer’s Disease This STTR grant strengthens the collaboration between NanoNewron and Rutgers University, the State University of New Jersey, a leading academic institution Sept. 10, 2025 -- NanoNewron (“NanoNe

– Proceeds to support clinical trials of Kriya’s five lead pipeline programs, as well as the Company’s R&D and manufacturing engine for new product development – Sept. 10, 2025 -- Kriya Therapeutics, Inc. (“Kriya”), a clinical-stage biopharmaceutical company developing gene therapies to address common chronic diseases of high unmet need, today announced the closing of a $320 million Series D financing. The round was co-led by Patient Square Capital and Premji Invest, with participation from ot

Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital $125 million financing upfront with up to an additional $150 million tied to exercise of warrants Warrants exercisable at a 20% premium to purchase price Sept. 08, 2025 -- Belite Bio, Inc ("Belite Bio" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degene

Sept. 08, 2025 -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera’s concurrently announced private placement financing. Talphera expects to use the proceeds of th

Sept. 03, 2025 -- MicrobiotiX, a biotech developing novel bacteriophage-based therapeutics, announced on the 29th that it has completed an extended Series B investment round totaling 20 billion KRW. MicrobiotiX’s cumulative investment amount across rounds has now reached 29 billion KRW. Following a 15 billion KRW Series B investment secured in October of 2024, MicrobiotiX completed the final closing of the round this month by securing an additional 5 billion KRW from new investors, including

- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - Sept. 02, 2025 -- Zenas BioPharma, Inc. (Nasdaq: ZBIO), and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of

Last patient last visit (LPLV) was reached for the 127 adult and elderly patients enrolled into the 12-week placebo-controlled trial with nispomeben (NRD.E1) Topline results are expected in November 2025 The trial builds on Phase 2a double-blind, randomized, dose-finding study comparing nispomeben to placebo with results showing a clinically meaningful placebo-corrected reduction in pain and favorable tolerability of nispomeben in patients with painful DPN [1] 2 September 2025 – Novaremed AG, a